logo

Prescription Drug Overdose: Boost for State Prevention

Sector: Commercial • Location: United States of America

Source: Grants.gov

Project
Archived

The purpose of this funding is to advance and evaluate comprehensive state-level interventions for preventing prescription drug misuse, abuse, and overdose. Interventions of interest address patient and prescriber behaviors that drive the prescription drug overdose epidemic, particularly the misuse and inappropriate prescribing of opioid pain relievers. Specifically, awardees will perform activiti

Project Information FAQ

Project Information

5 Q
The project “Prescription Drug Overdose: Boost for State Prevention” is an infrastructure initiative in the Commercial sector, located in United States of America. Taiyo aggregates data on it from Grants.gov.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

archived

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

The purpose of this funding is to advance and evaluate comprehensive state-level interventions for preventing prescription drug misuse, abuse, and overdose. Interventions of interest address patient and prescriber behaviors that drive the prescription drug overdose epidemic, particularly the misuse and inappropriate prescribing of opioid pain relievers. Specifically, awardees will perform activities that support at least two of the following complementary key prevention strategies to prevent prescription drug misuse, diversion, and overdose: enhancing and maximizing prescription drug monitoring programs (PDMPs); improving and evaluating state health insurance mechanisms to prevent prescription drug misuse, diversion, and overdose (e.g., via Medicaid or workers’ compensation); and evaluating state-level laws, policies, and regulations (e.g., legislation regulating pain clinics, or supporting clinical practice guidelines). The primary outcomes of interest may vary by strategy. They might include programmatic outcomes (e.g., mandatory PDMP registration and use, enrollment in patient review and restriction programs), behavior change (e.g., decrease prescribing inconsistent with clinical guidelines, decreased doctor shopping), and/or health-related outcomes (e.g., decrease in emergency department visits due to misuse or abuse of controlled prescription drugs, decreased drug overdose death rate). State-level engagement is critical to the success of this FOA given the concentration of the authority to address the use and misuse of prescription drugs within state government. Multi-sector collaboration with partners that have shared authority over this issue is also needed (e.g., law enforcement, boards of pharmacy, medical boards, mental health and substance abuse services, medical centers, lead state agencies for Medicaid programs.) Applicants are therefore required to submit letters of support from state-level governmental entities and other partners depending on the strategies they pursue under their work plan.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data